Source: Annual Congress 2013 –Pulmonary circulation: treatment
Disease area: Interstitial lung diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Keir, T. Corte, L. Parfitt, T. Maher, P. Marino, E. Renzoni, K. Dimopoulos, M. Gatzoulis, B. Madden, L. Howard, P. Corris, K. O'Reilly, B. Hope-Gill, S. Birring, A. Wells, S. J. Wort (London, Newcastle upon Tyne, Southampton, Cardiff, United Kingdom; Sydney, Australia). LATE-BREAKING ABSTRACT: Bosentan in Pulmonary Hypertension associated with Fibrotic Idiopathic Interstitial Pneumonia:A Randomized, Double-Blind, Placebo-controlled Study. Eur Respir J 2013; 42: Suppl. 57, 1779

Member's Comments

No comment yet.

Related content which might interest you: LATE-BREAKING ABSTRACT: Efficacy of Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF): an Italian real life study Source: International Congress 2014 – IPF and surroundings Year: 2014 Pirfenidone in idiopathic pulmonary fibrosis - description of a German cohort Source: International Congress 2014 – ILDs 4 Year: 2014 Reduction in disease progression with nintedanib in the INPULSIS™ trials Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Effect of design modifications on trial outcomes in idiopathic pulmonary fibrosis (IPF): Analysis of data from ASCEND and CAPACITY (CAP) Source: International Congress 2014 – IPF and surroundings Year: 2014 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Predictors of efficacy of pirfenidone in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014 LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial Source: International Congress 2016 – IPF treatment I Year: 2016 Sensitivity analyses from the INPULSIS™ trials of nintedanib Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Safety and efficacy of pirfenidone in severe idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 3 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 LATE-BREAKING ABSTRACT: Current management of patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 3 Year: 2014 Clinical profile and early follow-up of patients receiving pirfenidone in the PIONEER observational study Source: International Congress 2014 – ILDs 6 Year: 2014 LATE-BREAKING ABSTRACT: Epidemiology of IPF in Italy Source: International Congress 2014 – ILDs 6 Year: 2014 Assessment of telomere length in the combined pulmonary fibrosis and emphysema syndrome Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Non-invasive haemodynamic measurement to detect treatment response in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Pulmonary interstitial glycogenosis: Diagnosis and follow-up Source: International Congress 2016 – Neonatal and paediatric multiorgan manifestations of acute and chronic pulmonary disease and use of treatments Year: 2016 Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 IPF - Idiopathic Pulmonary Fibrosis Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152 Year: 2019